Search

Your search keyword '"Rammeh, Soumaya"' showing total 19 results
Start Over Author "Rammeh, Soumaya" Publisher wiley
19 results on '"Rammeh, Soumaya"'

2. Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study

Author

Said, Rahma, primary, Hernández‐Losa, Javier, additional, Derouiche, Amine, additional, Moline, Teresa, additional, de Haro, Rosa Somoza Lopez, additional, Zouari, Skander, additional, Blel, Ahlem, additional, Rammeh, Soumaya, additional, and Ouerhani, Slah, additional

Published
2023
Full Text
View/download PDF

3. Pathologically confirmed women's breast cancer: A descriptive study of Tunisian and Algerian series

Author

Sassi, Farah, primary, Rekaya, Meriem Ben, additional, Belarbi, Ayed, additional, Chilla, Dalia, additional, Mansouri, Nada, additional, Achouri, Leila, additional, Saied, Essia, additional, Kassa, Reda, additional, Kacem, Linda Belhaj, additional, Ouezani, Manel, additional, Debabeche, Nadjiba, additional, Rebhi, Fatima, additional, and Rammeh, Soumaya, additional

Published
2023
Full Text
View/download PDF

4. An insight into the diagnostic and prognostic value of HOX A13 ’s expression in non‐muscle invasive bladder cancer

Author

Setti Boubaker, Nouha, primary, Gurtner, Aymone, additional, Trabelsi, Nesrine, additional, Manni, Isabella, additional, Blel, Ahlem, additional, Saadi, Ahmed, additional, Chakroun, Marouene, additional, Naimi, Zeineb, additional, Zaghbib, Selim, additional, Ksontini, Meriam, additional, Meddeb, Khedija, additional, Rammeh, Soumaya, additional, Ayed, Haroun, additional, Chebil, Mohamed, additional, Piaggio, Giulia, additional, and Ouerhani, Slah, additional

Published
2022
Full Text
View/download PDF

9. Dermoscopic features of mucosal lichen planus

Author

Rouai, Meriem, primary, Litaiem, Noureddine, additional, Hammami, Houda, additional, Bacha, Takwa, additional, Jones, Meriem, additional, Ksontini, Meriem, additional, Rammeh, Soumaya, additional, Mokni, Mourad, additional, and Zeglaoui, Faten, additional

Published
2021
Full Text
View/download PDF

10. Chronic macrocheilia: a clinico‐etiological series of 47 cases

Author

Toumi, Asma, primary, Litaiem, Noureddine, additional, Gara, Soumaya, additional, Chabchoub, Ines, additional, Bacha, Takwa, additional, Slouma, Maroua, additional, Ben Hassine, Lamia, additional, Rammeh, Soumaya, additional, Jones, Meriem, additional, and Zeglaoui, Faten, additional

Published
2021
Full Text
View/download PDF

18. An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.

Author

Setti Boubaker N, Gurtner A, Trabelsi N, Manni I, Blel A, Saadi A, Chakroun M, Naimi Z, Zaghbib S, Ksontini M, Meddeb K, Rammeh S, Ayed H, Chebil M, Piaggio G, and Ouerhani S

Subjects
Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Carcinogenesis, Humans, Neoplasm Invasiveness, Prognosis, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology
Abstract

Background: Several studies have interrogated the molecular pathways and their interacting genes underlying bladder cancer (BCa) tumorigenesis, yet, the role of homeobox genes is still poorly understood. Specifically, HOXA13, which plays an important role as a major actor in the urogenital tract's development., Methods: Immunohistochemical (IHC) staining was performed to inspect the differential expression of HOXA13 protein in non-muscle-invasive bladder cancer (NMIBC) and non-tumoral tissues. A semiquantitative scoring system was adopted to evaluate the IHC labeling. Correlation to clinical parameters was performed by descriptive statistics. Overall survival was estimated by the Kaplan-Meier method and Cox regression model. The functional HOX A13 protein association networks (PPI) were obtained using String 11.0 database., Results: HOX A13 exhibited cytoplasmic and nuclear staining. Its expression levels were lower in high-grade NMIBC (HG NMIBC) compared to low-grade ones (LG NMIBC). The expression of HOX A13 was correlated to tumor grade (LG/HG) (p = 0.036) and stage (TA/T1) (p = 0.036). Nevertheless, its expression was not correlated to clinical parameters and was not able to predict the overall survival of patients with HG NMIBC. Finally, PPI analysis revealed that HOX A13 seems to be a part of a molecular network holding mainly PBX1, MEIS, ALDH1A2, HOX A10, and HOX A11., Conclusion: The deregulation of HOX A13 is not associated with the prognosis of BCa. It seems to be rather implicated in the early initiation of urothelial tumorigenesis and thus may serve as a diagnostic marker in patients with NMIBC. Further experimentations on larger validation sets are mandatory., (© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

19. Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations.

Author

Fatnassi-Mersni G, Arfaoui AT, Cherni M, Jones M, Zeglaoui F, Ouzari HI, and Rammeh S

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Developing Countries statistics & numerical data, Female, Humans, Immunohistochemistry methods, Male, Melanoma diagnosis, Middle Aged, Molecular Targeted Therapy methods, Mutation, Sensitivity and Specificity, Sequence Analysis, DNA methods, Skin Neoplasms diagnosis, Skin Neoplasms metabolism, Tunisia epidemiology, Melanoma, Cutaneous Malignant, Melanoma metabolism, Proto-Oncogene Proteins B-raf metabolism, Skin Neoplasms pathology
Abstract

Background: Determination of BRAF status is mandatory for targeted therapy but it is not currently available in most developing countries., Aim: We aimed to analyze BRAF mutations in a series of cutaneous melanoma of Tunisian patients and to compare BRAF V600E mutation detection by immunohistochemistry to DNA sequencing., Patients and Methods: Archival formalin fixed paraffin embedded tissues from 28 patients with primary cutaneous melanoma were evaluated for the BRAF mutations by Sanger sequencing and immunohistochemistry., Results: BRAF mutations were detected in 19/28 (68%) of analyzed tumors. The sensitivity and specificity of immunohistochemistry compared to DNA sequencing for identification of the BRAF V600E mutation were 100%. We found five novel mutations, one of them had deleterious effect., Conclusion: The present study shows an intermediate frequency of mutations of the BRAF gene in cutaneous melanoma of Tunisian patients, and supports the use of immunohistochemistry as a screening test for the assessment of the BRAF V600E status in the management of melanoma in clinical practice., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results